← Back to Search

Monoclonal Antibodies

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing the safety of a new injectable drug called AMG 609 in people with non-alcoholic fatty liver disease (NAFLD). The goal is to see if the drug is safe and well-tolerated when given as a single dose.

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Group I: PlaceboExperimental Treatment1 Intervention
Participants will receive the matching placebo.
Group II: AMG 609Experimental Treatment1 Intervention
Up to 7 cohorts ranging by various dose levels.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
AMG 609
2021
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,442 Previous Clinical Trials
1,397,697 Total Patients Enrolled
MDStudy DirectorAmgen
980 Previous Clinical Trials
941,453 Total Patients Enrolled
~10 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top